



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 25 Oct 2021 (#35)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)**

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices

**[NOT-TW-21-008](#) Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Research for Chronic Disease Prevention Across the Lifespan (R01 Clinical Trial Optional)**. The Fogarty International Center (FIC) and partner National Institutes of Health (NIH) Institutes and Centers (ICs) have reorganized NIH participation in the Global Alliance for Chronic Diseases (GACD) and intends to publish Funding Opportunity Announcements (FOAs) that will utilize yearly Notices of Special Interest (NOSIs) to invite applications for implementation research on noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and marginalized Native American/Alaska Native populations in the United States. These FOAs will utilize the R01 (Clinical Trial Optional) and R61/R33 (Clinical Trial Required) activity codes. Yearly NOSIs will be utilized to solicit applications in response to these FOAs for the upcoming call topics highlighted below. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Applications will be accepted from US and LMIC institutions only.

**The 2021-2023 call topics are anticipated as follows:**

- **2021:** NCD prevention in adolescents, young adults and other vulnerable stages across the life course: implementation research focused on interventions that address common NCD risk factors, reduce health risk and/or enhance positive health and lifestyle behaviors in young people and in other vulnerable life course stages (e.g., early childhood, elderly), and develop/test implementation strategies to support the uptake and scale up of these interventions.
- **2022:** Interventions in urban environments to reduce NCD risk: implementation research focused on individual, community, and/or structural level interventions that can reduce NCD risk and/or maximize the health-

promoting potential of cities. Trans-disciplinary and multi-sectoral partnerships among the health, urban planning, and behavioral sciences will be encouraged.

- **2023:** Integrated management of multi-morbidity: implementation research focused on integrating interventions in clinical, community, and public health settings for optimizing management and care for patients coping with multiple conditions.

## Notices of Special Interest

**[NOT-AI-21-072](#) Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity.** This Notice of Special Interest (NOSI) solicits research on immunologic characterization of mice with diverse microbial exposures (commonly referred to as “dirty mice”) to determine their usefulness as research tools to advance understanding of human immune function in homeostasis and in response to infectious or immune-mediated diseases. This notice applies to due dates on or after February 16, 2022 and subsequent receipt dates through January 7, 2025. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of this announcement through the expiration date of this notice.

- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

**[NOT-AI-21-080](#) Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes.** The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use. This Notice of Special Interest (NOSI) replaces NOT-AI-21-067, which was rescinded with the issuance of this Notice. This Submit applications for this initiative using one of the following FOAs or any reissues of these announcements through the expiration date of this Notice. Notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through January 7, 2025. Submit applications for this initiative using one of the following FOAs or any reissues of these announcements through the expiration date of this Notice.

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

## Funding Opportunity Announcements (FOA)

### 1. Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-049](#)

**Type:** U01

**Application Due Date:** January 11, 2022; June 07, 2022; September 13, 2022 through to September 13, 2024 Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies”, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for “liquid biopsies”, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$250,000 direct costs per year. The maximum period is 5 years.

### 2. Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-21-075](#)

**Type:** R01

**Application Due Date:** February 08, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to expand our understanding of protozoan parasite persistence mechanisms and provide research tools and strategies to enable identification and credentialing of novel treatments for persistent protozoan pathogens.

**Budget:** NIAID intends to commit \$4,500,000 in FY2022 to fund up to 9 awards. Application budgets may not exceed \$500,000 (direct costs) per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. Expanding Differentiated Care Approaches for Adolescents Living with HIV (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-22-105](#)

**Type:** R01

**Application Due Date:** January 06, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for Research Project Grants (R01) that will evaluate differentiated models of care for adolescents and young adults (referred to in this FOA as youth) who are living with HIV around the world. Differentiated care models can be designed to maintain or improve health outcomes along the HIV care continuum for youth living with HIV (YLWH). This FOA uses the R01 grant mechanism, while [RFA-MH-22-106](#) uses the R34 mechanism. Applications with preliminary data or those including longitudinal analysis should consider using the R01 mechanism. Applicants proposing to develop and pilot test an intervention should consider the R34 mechanism.

**Budget:** NIMH intends to commit \$2M in FY 2022 to fund 4-6 awards in response to this FOA and the companion ([RFA-MH-22-106](#)). Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105